Our Latest News
Malaika Vx and Fundamentum Capital Announce Multi-Target Research Collaboration to Advance Medical Countermeasure Therapeutics
Toronto, Canada, December 2024
Fundamentum Capital has entered into a research and investment collaboration with Malaika Vx to discover and develop cutting-edge medical countermeasures, including novel vaccines and therapeutics. Leveraging Malaika Vx’s proprietary platform technologies, this partnership aims to address critical global health challenges, with a particular focus on bioterrorism threats and pandemic diseases such as SARS, hemorrhagic fevers, and influenza.
Malaika Vx will apply its expertise and technologies to multiple medical countermeasure targets, including advanced vaccine candidates and platform solutions capable of rapid deployment. Once discovery efforts advance to a prescribed stage, Fundamentum will have the option to acquire exclusive worldwide rights to further develop and commercialize products generated through the collaboration.
“We believe this collaboration with Malaika Vx represents a significant opportunity to generate transformative medical countermeasures by leveraging their cutting-edge vaccine technologies and computational biology expertise,” said Eric Andrade, Managing Director, International, of Fundamentum Capital. “Our shared goal is to deliver innovative therapeutics and vaccines to those at risk, particularly from emerging health threats and bioterrorism events.”
The collaboration will leverage Malaika’s purpose-built computational drug discovery and vaccine development engine, which integrates biophysical and computational insights to rapidly identify and optimize candidates. Malaika’s current pipeline includes first-in-class vaccine candidates that address significant unmet needs across both civilian and defense sectors.
“Malaika Vx is thrilled to partner with Fundamentum Capital, a global leader in bio-innovation and dual-use investments. This collaboration underscores our shared commitment to global health equity and biosecurity,” said Dr. Jo Kennelly, CEO of Malaika Vx. “By combining our platform’s capabilities with Fundamentum Capital’s strategic investment and development expertise, we can accelerate the discovery and delivery of life-saving medical countermeasures to underserved populations worldwide.”
Under the terms of the collaboration, Malaika will receive an initial payment to advance its vaccine development programs, including bioterrorism-related threats. Malaika is also eligible to receive milestone payments upon achieving specified discovery, development, approval, and sales benchmarks, as well as tiered royalties based on annual sales of products developed through the collaboration. Fundamentum Capital retains an exclusive worldwide license option for development candidates discovered under the agreement.
About Malaika Vx
Malaika Vx is a biotechnology innovator specializing in vaccine development and medical countermeasures. With a mission to promote global health equity and biosecurity, Malaika Vx develops transformative solutions to address diseases with pandemic and bioterrorism potential, leveraging cutting-edge platform technologies to ensure accessibility and impact for underserved populations worldwide.
About Fundamentum Capital
Fundamentum Capital is a specialized global venture fund at the intersection of scientific discovery and market opportunity. We are dedicated to accelerating growth-stage bioinnovation enterprises that develop high-impact technologies serving both civilian and defense sectors while addressing critical global challenges.